•
Dec 31, 2024

3M Q4 2024 Earnings Report

3M reported mixed Q4 2024 results with a slight sales increase and adjusted EPS decrease, alongside full-year 2025 financial guidance.

Key Takeaways

3M reported Q4 sales of $6.0 billion, a 0.1% increase year-over-year, and adjusted sales of $5.8 billion with organic growth up 2.1%. GAAP EPS from continuing operations was $1.33, up 17% year-over-year, while adjusted EPS from continuing operations was $1.68, down 2%. The company initiated full-year 2025 financial guidance, projecting adjusted total sales growth of 0.5 to 1.5 percent and adjusted EPS in the range of $7.60 to $7.90.

Q4 sales increased slightly by 0.1% year-over-year to $6.0 billion.

GAAP EPS from continuing operations rose 17% year-over-year to $1.33.

Adjusted EPS from continuing operations decreased by 2% year-over-year to $1.68.

Full-year 2025 guidance projects adjusted EPS in the range of $7.60 to $7.90.

Total Revenue
$6.01B
Previous year: $8.01B
-25.0%
EPS
$1.68
Previous year: $2.42
-30.6%
Organic Revenue Growth
0.02%
Previous year: -1.9%
-101.1%
Gross Profit
$2.27B
Previous year: $3.34B
-32.1%
Cash and Equivalents
$5.6B
Previous year: $5.93B
-5.6%
Free Cash Flow
$1.53B
Previous year: $1.96B
-21.9%
Total Assets
$39.9B
Previous year: $50.6B
-21.2%

3M

3M

3M Revenue by Segment

Forward Guidance

3M provided full-year 2025 expectations, including adjusted total sales growth in the range of 0.5 to 1.5 percent, reflecting adjusted organic sales growth of 2 to 3 percent, and adjusted EPS in the range of $7.60 to $7.90.

Positive Outlook

  • Adjusted total sales growth in the range of 0.5 to 1.5 percent.
  • Adjusted organic sales growth of 2 to 3 percent.
  • Adjusted EPS in the range of $7.60 to $7.90.
  • Adjusted operating cash flow of $5.2 to $5.3 billion.
  • Approximately 100 percent adjusted free cash flow conversion.

Challenges Ahead

  • 3M cannot forecast certain items required to develop meaningful comparable GAAP financial measures without unreasonable effort.
  • Special items such as net costs for significant litigation are subject to limitations in predictability.
  • Projected divestiture gains and costs are difficult to forecast.
  • Changes in value of Solventum ownership are unpredictable.
  • Estimates of income and associated activity of exited manufactured PFAS products are subject to limitations.

Revenue & Expenses

Visualization of income flow from segment revenue to net income